WO2009074862A1 - Polymorphic forms of a 3-pyrrole substituted 2-indolinone - Google Patents
Polymorphic forms of a 3-pyrrole substituted 2-indolinone Download PDFInfo
- Publication number
- WO2009074862A1 WO2009074862A1 PCT/IB2008/003458 IB2008003458W WO2009074862A1 WO 2009074862 A1 WO2009074862 A1 WO 2009074862A1 IB 2008003458 W IB2008003458 W IB 2008003458W WO 2009074862 A1 WO2009074862 A1 WO 2009074862A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sunitinib base
- polymorphic form
- sunitinib
- solvent
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Sunitinib (Compound I) is the international commonly accepted name for N- [2- (diethylamino)ethyl]-5-[(2)-(5-fluoro-l,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4- dimethyl-lH-pyrrole-3-carboxamide, and has an empirical formula Of C 22 H 27 FN 4 O 2 , and a molecular weight of 398.47. Sunitinib is an active pharmaceutical substance indicated for the treatment of abnormal cell growth, such as cancer, in mammals, particularly in humans.
- the malate salt of sunitinib has been selected for medical purpose and is commercially marketed under the trade name of SUTENTTM for the treatment of renal cell carcinoma and gastrointestinal stromal tumors.
- Sunitinib base and its malate salt are described in U.S. Patent No. 6,573,293 ("the '293 patent"), which is incorporated herein by reference.
- Example 80 (Alternative Synthesis) of the '293 patent describes the preparation of sunitinib base via condensation of 5-fluoro-l,3-dihydroindol-2-one and N-[2-(diethylamino)ethyl]-5-formyl- 2,4-dimethyl-lH-pyrrole-3-carboxamide, in the presence of pyrrolidine and ethanol.
- sunitinb base Form III the crystalline form of sunitinib base obtained, referred to herein as sunitinib base Form III, has been characterized herein by X-ray powder diffraction (XRD), infrared (IR) spectroscopy, and differential scanning calorimetry (DSC).
- XRD X-ray powder diffraction
- IR infrared
- DSC differential scanning calorimetry
- sunitinib base Form III presents a low solubility profile, which makes dissolving sunitinib and the preparation of corresponding pharmaceutically acceptable salts troublesome. This observation is in accordance with the European Public Assessment Report provided for SUTENTTM which discloses that sunitinib is classified as a low solubility compound according to the biopharmaceutical classification.
- the low solubility of sunitinib base Form III would involve the use of large amounts of suitable solvents or mixture of solvents and/or the use of particular conditions aimed to improve the solubility of sunitinib base Form III and/or long reaction times for processes using sunitinib, which may represent an important drawback, especially for processes on an industrial scale.
- no other polymorph of sunitinib, other than sunitinib base Form III is reported in the literature. Additionally, there is no crystal structure data in the literature for sunitinib base Form III.
- Polymorphism is common among chemical substances and is commonly defined as the ability of a substance to exist in two or more crystalline phases that have a different arrangement and/or conformation of the molecules in the crystal lattice. Different polymorphs typically differ in their physical properties such as, for example, melting point, solubility, and chemical reactivity. Thus, the particular characteristics of the respective polymorphs can appreciably influence the solubility profile of a chemical substance. Further, the particular characteristics of the respective polymorphs can appreciably influence pharmaceutical properties such us dissolution rate and bioavailability. [0009] Accordingly, there is a need to identify and isolate new polymorphic forms of sunitinib base, as well as to develop processes for producing sunitinib base in new polymorphic forms. In addition, there is a need for improved pharmaceutical compositions comprising sunitinib base in one or more polymorphic forms.
- the present invention provides crystalline polymorphic forms of iV-[2- (diethylamino)ethyl]-5-[(Z)-(5-fluoro-l,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4- dimethyl-lH-pyrrole-3-carboxamide, that is, sunitinib base, including polymorphic Form I, Form II, impure Form III, Form IV, and mixtures thereof.
- the present invention also provides processes for preparing crystalline polymorphic forms of sunitinib base, including polymorphic Form I, Form II, impure and known Form III, Form IV, and mixtures thereof.
- the present invention further provides processes for preparing pharmaceutically acceptable salts of sunitinib base (e.g., sunitinib malate) using crystalline polymorphic forms of sunitinib base, including polymorphic Form I, Form II, known Form III, Form IV, and mixtures thereof.
- sunitinib base e.g., sunitinib malate
- crystalline polymorphic forms of sunitinib base including polymorphic Form I, Form II, known Form III, Form IV, and mixtures thereof.
- the present invention also provides pharmaceutical compositions comprising N- [2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-l,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4- dimethyl-lH-pyrrole-3-carboxamide, that is, sunitinib base, including crystalline polymorphic Form I, Form II, Form III known and in impure forms, Form IV, mixtures thereof, and salts thereof, preferably compositions comprising a polymorphic form of sunitinib base selected from the group consisting of polymorphic Form I, polymorphic Form II, polymorphic Form IV, and mixtures of any one or more of polymorphic Form I, polymorphic Form II, polymorphic Form IV, and mixtures of at least one of polymorphic Form I, polymorphic Form II, polymorphic Form IV with impure Form III or known Form III.
- Figure 1 is the X-ray powder diffractogram (XRD) of sunitinib base polymorphic
- Figure 2 is the Infrared (IR) spectrum of sunitinib base polymorphic Form I.
- Figure 3 is the Differential Scanning Calorimetry (DSC) thermogram in an open pan of sunitinib base polymorphic Form I.
- Figure 4 is the XRD of sunitinib base polymorphic Form II.
- Figure 5 is the IR spectrum of sunitinib base polymorphic Form II.
- Figure 6 is the Differential Scanning Calorimetry (DSC) thermogram in an open pan of sunitinib base polymorphic Form II.
- Figure 7 is the XRD of sunitinib base impure polymorphic Form III.
- Figure 8 is the IR spectrum of sunitinib base impure polymorphic Form III.
- Figure 9 is the DSC thermogram in an open pan of sunitinib base impure polymorphic Form III.
- Figure 10 is the XRD of sunitinib base polymorphic Form IV.
- Figure 11 is the IR spectrum of sunitinib base polymorphic Form IV.
- Figure 12 is the DSC thermogram in an open pan of sunitinib base polymorphic
- Figure 13 is the XRD of sunitinib base polymorphic Form III.
- Figure 14 is the IR spectrum of sunitinib base polymorphic Form III.
- Figure 15 is the DSC thermogram in an open pan of sunitinib base polymorphic
- sunitinib base can exist in several crystalline forms. These crystalline forms of sunitinib base have been prepared and characterized as described herein and are referred to herein as polymorphic Form I, Form II, Form III known and impure forms, and Form IV. The crystalline forms of sunitinib base can also be mixtures.
- the present invention provides crystalline polymorphic forms of ⁇ f-[2-(diethylamino)ethyl]-5-[(Z)-(5-fiuoro-l ,2-dihydro-2-oxo-3H- indol-3-ylidine)methyl]-2,4-dimethyl-l//-pyrrole-3-carboxamide, that is, sunitinib base, characterized using various analytical methods, including, for example, XRD, IR, and DSC.
- the present invention provides N-[2-
- the present invention provides sunitinib base polymorphic
- Form I sunitinib base includes peaks at approximately 4.5, 7.5, 9.1, 11.1, 13.1, 15.6, 16.3, 17.5, 18.8, 19.3, 25.0,
- the present invention provides sunitinib base polymorphic
- Form I sunitinib base includes peaks at approximately 3471, 3400, 3170, 3042, 2968, 2825, 1671, 1646, 1615,
- the present invention provides sunitinib base polymorphic
- Form I having a DSC thermogram in an open pan as substantially shown in Figure 3.
- Figure 3 illustrates the DSC thermogram in an open pan of sunitinib base polymorphic Form I which has an endothermic peak at approximately 227.2 °C with an onset of 224.5 °C.
- the present invention provides N-[2-
- the present invention provides sunitinib base polymorphic
- Form II sunitinib base includes peaks at approximately 7.2, 9.4, 10.7, 11.2, 13.6, 14.9, 16.0, 18.2, 18.9, 21.1, 22.0,
- the present invention provides sunitinib base polymorphic
- Form II having an IR spectrum as substantially shown in Figure 5.
- Form II sunitinib base includes peaks at approximately 3464, 3219, 2672, 1626, 1570, 1516, 1473, 1432, 1404,
- the present invention provides sunitinib base polymorphic
- FIG. 6 illustrates the DSC thermogram in an open pan of sunitinib base polymorphic Form II which has an endothermic peak at approximately 256.6 0 C with an onset of 252.7 °C.
- the present invention provides characterization data for
- the present invention provides sunitinib base impure polymorphic Form III having an XRD pattern substantially as shown in Figure 7. Impure
- Form III sunitinib base includes peaks at approximately 4.6, 9.0, 11.3, 13.0, 15.1, 16.6, 18.2,
- the present invention provides sunitinib base impure polymorphic Form III having an IR spectrum as substantially shown in Figure 8. Impure
- Form III sunitinib base includes peaks at approximately 3464, 3220, 2967, 1677, 1625, 1589,
- the present invention provides sunitinib base impure polymorphic Form III having a DSC thermogram in an open pan as substantially shown in Figure 9.
- Figure 9 illustrates the DSC thermogram in an open pan of sunitinib base impure polymorphic Form III which has an endothermic peak at approximately 230.8 °C with an onset of 226.3 °C.
- the present invention provides sunitinib base known polymorphic Form III having an XRD pattern substantially as shown in Figure 13.
- Form III sunitinib base includes peaks at approximately 4.6, 8.9, 9.8, 12.9, 15.1, 16.5, 17.7,
- the present invention provides sunitinib base known polymorphic Form III having an IR spectrum as substantially shown in Figure 14.
- Known polymorphic Form III having an IR spectrum as substantially shown in Figure 14.
- Form III sunitinib base includes peaks at approximately 3418, 3298, 3227, 2966, 2926, 2868,
- the present invention provides sunitinib base known polymorphic Form III having a DSC thermogram in an open pan as substantially shown in
- Figure 15 illustrates the DSC thermogram in an open pan of sunitinib base known polymorphic Form III which has an endothermic peak at approximately 244.5 °C with an onset of 242.2 °C.
- the present invention provides
- the present invention provides sunitinib base polymorphic
- Form IV sunitinib base includes peaks at approximately 4.2, 7.6, 8.4, 11.4, and 25.2 degrees 2 ⁇ ( ⁇ 0.2 degrees).
- the present invention provides sunitinib base polymorphic
- Form IV sunitinib base includes peaks at approximately 3043, 2968, 2823, 1672, 1626, 1569, 1478, 1383, 1327,
- the present invention provides sunitinib base polymorphic
- the present invention provides processes for preparing crystalline polymorphic forms of N-[2-(diethylamino)ethyl]-5-[(Z)- (5 -fluoro- 1 ,2-dihydro-2-oxo-3H-indol-3 -ylidine)methyl] -2,4-dimethyl- 1 H-pyrrole-3 - carboxamide (i.e., sunitinib base).
- processes for preparing crystalline polymorphic forms of sunitinib base typically comprise forming a suspension or a solution of sunitinib base in a solvent, and separating or isolating the polymorphic form of sunitinib base from the solvent.
- the sunitinib base used for preparing polymorphic forms of sunitinib base of the present invention can be from any suitable source.
- the sunitinib base starting material can be obtained by any known method.
- the sunitinib base starting material can be other polymorphic forms of sunitinib base (e.g., Form I, Form II, known Form III, impure Form III, Form IV, and mixtures thereof).
- Illustrative solvents useful in processes of the invention include, for example, dichloromethane, methyl tert-buty ⁇ ether, n-butyl acetate, /-propyl acetate, water, toluene, heptane, dimethylformamide, methanol, ethanol, tetrahydrofuran, 2-propanol, rc-butanol, 2-butanone, acetonitrile, chloroform, and mixtures thereof.
- the present invention provides a process for preparing sunitinib base polymorphic Form I, said process comprising (i) suspending sunitinib base in a solvent to form a suspension and (ii) removing the solvent from said suspension, to give sunitinib base polymorphic Form I.
- step (i) is conducted at a temperature of from about 25 0 C to about 70 0 C.
- step (ii) is conducted by filtering the suspension.
- the solvent comprises dichloromethane, ⁇ -butyl acetate, /-propyl acetate, water, toluene, heptane, or a 20:80 mixture of water and ethanol.
- the present invention provides a process for preparing sunitinib base polymorphic Form II, said process comprising (i) dissolving sunitinib base in a solvent which comprises methanol to form a solution, and (ii) removing the solvent from said solution, to give sunitinib base polymorphic Form II.
- the solvent is methanol.
- step (i) is conducted at reflux. It is also preferred that step (ii) is conducted by stirring the solution at room temperature to obtain a suspension and filtering the suspension.
- the present invention provides a process for preparing sunitinib base impure polymorphic Form III, said process comprising (i) suspending sunitinib base in a solvent to form a suspension and (ii) removing the solvent from said suspension, to give sunitinib base impure polymorphic Form III.
- step (i) is conducted at a temperature of from about 50 0 C to about 70 0 C.
- step (ii) is conducted by evaporating the solvent.
- the solvent comprises tetrahydrofuran, ethanol, 2-propanol, rc-butanol, 2-butanone, or acetonitrile.
- the present invention provides a process for preparing sunitinib base known polymorphic Form III, said process comprising (i) precipitating sunitinib base known polymorphic Form III from a solvent to form a suspension and (ii) removing the solvent from said suspension, to give sunitinib base polymorphic Form III.
- step (i) is carried out directly from the reaction crude.
- the solvent comprises ethanol, 2-propanol, or n-butanol.
- the present invention provides a process for preparing sunitinib base known polymorphic Form III, said process comprising (i) suspending sunitinib base in a solvent to form a suspension and (ii) removing the solvent from said suspension, to give sunitinib base polymorphic Form III.
- step (i) is conducted at a temperature not higher than about 95 0 C.
- the solvent comprises acetonitrile, ethanol, 2-propanol, or «-butanol.
- the present invention provides a process for preparing sunitinib base known polymorphic Form III, said process comprising (i) dissolving sunitinib base in H-butanol to form a solution, and (ii) removing the solvent from said solution, to give sunitinib base polymorphic Form III.
- step (i) is conducted at a temperature higher than about 110 0 C.
- step (ii) is conducted by stirring the solution at about 0-5 0 C to obtain a suspension and filtering the suspension.
- the present invention provides a process for preparing sunitinib base polymorphic Form IV, said process comprising (i) suspending sunitinib base in chloroform to form a suspension and (ii) removing the chloroform from said suspension, to give sunitinib base polymorphic Form IV.
- step (i) is conducted at a temperature of about 50 0 C.
- step (ii) is conducted by evaporating the chloroform.
- the present invention provides a process for preparing pharmaceutically acceptable salts of sunitinib (e.g., sunitinib malate) comprising reacting sunitinib base with a salt forming reagent, wherein the sunitinib base is selected from the group consisting of sunitinib base polymorphic Form I, Form II, or Form IV. It is also possible to form the salt form of mixtures of sunitinib base polymorphic Form I, Form II, known Form III and Form IV in all the various combinations, such as the salt form of sunitinib base polymorphic Forms I and II, Forms I and known III, Forms II and known III, and the like, as well as all four of Forms I-IV.
- the salt forming reagent is a malate salt forming reagent.
- the present invention also provides pharmaceutical compositions comprising sunitinib base and salts of sunitinib base polymorphic Form I, Form II, Form III, Form IV, and mixtures thereof.
- the present invention provides compositions comprising a polymorphic form of sunitinib base selected from the group consisting of polymorphic Form I, polymorphic Form II, polymorphic Form IV, and mixtures of any two or more of polymorphic Form I, polymorphic Form II, polymorphic Form IV.
- the present invention provides compositions comprising mixtures of at least one of polymorphic Form I, polymorphic Form II, polymorphic Form IV with impure Form III or known Form III.
- compositions can comprise mixtures of any of the polymorphic forms of sunitinib base and salts of polymorphic forms of sunitinib base in all various combinations and permutations.
- the salts of sunitinib base is the malate salt.
- DSC measurements were performed in vented pan at a scan rate of 10 °C/minute from 25.0 °C to 290.0 °C under a nitrogen purge with a DSC823 available from Mettler-
- sunitinib base polymorphic Form III is the polymorphic form obtained in the prior art.
- This example illustrates a process for preparing sunitinib base polymorphic Form
- Sunitinib base 500 mg was suspended in water (2.5 mL), adjusted to p ⁇ 11 and stirred for 1 hour. The mixture was filtered and resuspended in water (2.5 mL) for 1 hour.
- the mixture was filtered and dried under vacuum at 40 0 C.
- sunitinib base 100 mg was suspended in a solvent (1 mL) and heated (in a closed vial) at the temperature indicated in Table 1 for 1 hour. The mixtures were allowed to cool to ambient temperature, stirred for 24 hours at this temperature before evaporation of the solvent (by opening the vial and allowing to evaporate under ambient temperature pressure conditions). The results are summarized in Table 1.
- This example illustrates a process for preparing sunitinib base polymorphic Form
- Sunitinib base 300 mg was dissolved in methanol (25 mL) at reflux and allowed to cool to ambient temperature. The mixture was filtered and dried under vacuum at 40 0 C.
- sunitinib base 100 mg was suspended in a solvent (1 mL) and heated (in a closed vial) at the temperature indicated in Table 2 for 1 hour. The mixtures were allowed to cool to ambient temperature, stirred for 24 hours at this temperature before evaporation of the solvent (by opening the vial and allowing to evaporate under ambient temperature pressure conditions). The results are summarized in Table 2.
- sunitinib base 100 mg was suspended in solvent (1 mL) and heated (in a closed vial) at the temperature indicated in Table 3 for 1 hour. The mixtures were allowed to cool to ambient temperature, stirred for 24 hours at this temperature before evaporation of the solvent (by opening the vial and allowing to evaporate under ambient temperature pressure conditions, except entry 21 that was dried under vacuum). The results are summarized in Table 3.
- This example illustrates a process for preparing sunitinib base polymorphic Form
- Sunitinib base (100 mg) was suspended in chloroform (1 mL) and heated (in a closed vial) at 50 0 C for 1 hour. The mixture was allowed to cool to ambient temperature, stirred for 24 hours at this temperature before evaporation of the solvent (by opening the vial and allowing to evaporate under ambient temperature pressure conditions).
- This example illustrates a process for preparing sunitinib base polymorphic Form III in accordance with an embodiment of the invention.
- This example illustrates a process for preparing sunitinib base polymorphic Form III in accordance with an embodiment of the invention.
- N-[2-(diethylamino)ethyl]-5-formyl-2,4-dimethyl-lH-pyrrole-3-carboxamide (10.02 g), 5-fluoro-2-oxindole (5.70 g) and «-butanol (100 mL) were stirred at room temperature. Pyrrolidine (160 ⁇ L) was then added and the suspension was heated to 94 0 C. Complete dissolution of the materials was observed at 47 °C, and once at 94 °C an orange solid started to crystallize.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2709083A CA2709083A1 (en) | 2007-12-12 | 2008-12-12 | Polymorphic forms of a 3-pyrrole substituted 2-indolinone |
US12/747,762 US8389562B2 (en) | 2007-12-12 | 2008-12-12 | Polymorphic forms of a 3-pyrrole substituted 2-indolinone |
CN200880126370.2A CN101939314B (en) | 2007-12-12 | 2008-12-12 | Polymorphic forms of a 3-pyrrole substituted 2-indolinone |
EP08860304A EP2229380A1 (en) | 2007-12-12 | 2008-12-12 | Polymorphic forms of a 3-pyrrole substituted 2-indolinone |
IL206344A IL206344A0 (en) | 2007-12-12 | 2010-06-13 | Polymorphic forms a 3- polyrole substituted 2-indolinone |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1311707P | 2007-12-12 | 2007-12-12 | |
US61/013,117 | 2007-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009074862A1 true WO2009074862A1 (en) | 2009-06-18 |
Family
ID=40589748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2008/003458 WO2009074862A1 (en) | 2007-12-12 | 2008-12-12 | Polymorphic forms of a 3-pyrrole substituted 2-indolinone |
Country Status (6)
Country | Link |
---|---|
US (1) | US8389562B2 (en) |
EP (1) | EP2229380A1 (en) |
CN (1) | CN101939314B (en) |
CA (1) | CA2709083A1 (en) |
IL (1) | IL206344A0 (en) |
WO (1) | WO2009074862A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010023473A2 (en) * | 2008-08-25 | 2010-03-04 | Generics [Uk] Limited | Novel crystalline form and processes for its preparation |
WO2010023474A1 (en) * | 2008-08-25 | 2010-03-04 | Generics [Uk] Limited | Novel polymorphs of sunitinib and processes for their preparation |
EP2220072A2 (en) * | 2007-11-21 | 2010-08-25 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
EP2280960A1 (en) * | 2008-04-16 | 2011-02-09 | Natco Pharma Limited | Novel polymorphic forms of sunitinib base |
WO2011100325A2 (en) | 2010-02-09 | 2011-08-18 | Sicor Inc. | Polymorphs of sunitinib salts |
EP3539536A1 (en) | 2018-03-15 | 2019-09-18 | MH10 Spolka z ograniczona odpowiedzialnoscia | A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020156292A1 (en) * | 2000-02-15 | 2002-10-24 | Tang Peng Cho | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA76483C2 (en) * | 2001-08-15 | 2006-08-15 | Upjohn Co | Crystalline form of malic acid salt of n-|2-(diethylamino)ethyl|-5-|(5-fluoro -2--oxo-3n-indol-3-ylidene)methyl]-2,4- dimelhyl-1n-pyrrole-3-carboxamide (variants), a method for preparing and compositions thereof |
CN1758914A (en) * | 2003-02-24 | 2006-04-12 | 苏根公司 | Treatment of excessive osteolyisis with indolinone compounds |
US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
-
2008
- 2008-12-12 CN CN200880126370.2A patent/CN101939314B/en not_active Expired - Fee Related
- 2008-12-12 US US12/747,762 patent/US8389562B2/en active Active
- 2008-12-12 WO PCT/IB2008/003458 patent/WO2009074862A1/en active Application Filing
- 2008-12-12 EP EP08860304A patent/EP2229380A1/en not_active Withdrawn
- 2008-12-12 CA CA2709083A patent/CA2709083A1/en not_active Abandoned
-
2010
- 2010-06-13 IL IL206344A patent/IL206344A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020156292A1 (en) * | 2000-02-15 | 2002-10-24 | Tang Peng Cho | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2220072A2 (en) * | 2007-11-21 | 2010-08-25 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
EP2280960A1 (en) * | 2008-04-16 | 2011-02-09 | Natco Pharma Limited | Novel polymorphic forms of sunitinib base |
US8466190B2 (en) | 2008-04-16 | 2013-06-18 | Natco Pharma Limited | Polymorphic forms of Sunitinib base |
WO2010023473A2 (en) * | 2008-08-25 | 2010-03-04 | Generics [Uk] Limited | Novel crystalline form and processes for its preparation |
WO2010023474A1 (en) * | 2008-08-25 | 2010-03-04 | Generics [Uk] Limited | Novel polymorphs of sunitinib and processes for their preparation |
WO2010023473A3 (en) * | 2008-08-25 | 2010-05-14 | Generics [Uk] Limited | Crystalline form of sunitinib and processes for its preparation |
WO2011100325A2 (en) | 2010-02-09 | 2011-08-18 | Sicor Inc. | Polymorphs of sunitinib salts |
EP3539536A1 (en) | 2018-03-15 | 2019-09-18 | MH10 Spolka z ograniczona odpowiedzialnoscia | A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i |
Also Published As
Publication number | Publication date |
---|---|
CA2709083A1 (en) | 2009-06-18 |
IL206344A0 (en) | 2010-12-30 |
EP2229380A1 (en) | 2010-09-22 |
CN101939314B (en) | 2014-04-02 |
CN101939314A (en) | 2011-01-05 |
US8389562B2 (en) | 2013-03-05 |
US20100286410A1 (en) | 2010-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8703967B2 (en) | Crystal form of sunitinib malate | |
EP2253629A1 (en) | Polymorphs of racemic sunitinib malate, compositions containing them and preparation thereof | |
US8389562B2 (en) | Polymorphic forms of a 3-pyrrole substituted 2-indolinone | |
WO2012068441A2 (en) | Intedanib salts and solid state forms thereof | |
EP1844016A1 (en) | Polymorph and solvates of aripiprazole | |
US8252805B2 (en) | Forms of lapatinib ditosylate and processes for preparation thereof | |
EP1686117A1 (en) | Polymorph and solvates of aripiprazole | |
EP2342195B1 (en) | Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt | |
WO2009156837A2 (en) | Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt | |
EP3230280A1 (en) | Process for preparation of luliconazole | |
US20080167477A1 (en) | Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same | |
EP2373643A2 (en) | Novel polymorphs of sunitinib malate | |
US20160168166A1 (en) | A process for preparing rifaximin k | |
WO2008114279A2 (en) | Novel polymorphs of lamivudine | |
EP2274303A1 (en) | Processes for preparing sunitinib and salts thereof | |
US11407759B2 (en) | Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | |
US20100256392A1 (en) | Polymorphs of sunitinib base and processes for preparation thereof | |
US8278484B2 (en) | Process for preparing a benzoylbenzeneacetamide derivative | |
WO2013181251A1 (en) | Crizotinib hydrochloride salt in crystalline | |
WO2008038143A2 (en) | Novel solid forms of rimonabant and synthetic processes for their preparation | |
EP2260037A2 (en) | A polymorphic form of a pyrazino [2,3-h] [3] benzazepine derivative | |
WO2010131118A2 (en) | Polymorphs of etravirine and processes for preparation thereof | |
WO2007084697A2 (en) | Process for preparing a crystalline form of tegaserod maleate | |
WO2016188506A1 (en) | Solid forms of 5-fluoro-3-phenyl-2-[(1s)-1-(9h-purin-6-ylamino)propyl]quinazolin-4-one and preparation thereof | |
US20090030207A1 (en) | Polymorphs of Dolasetron base and process for preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880126370.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08860304 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2709083 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4947/DELNP/2010 Country of ref document: IN |
|
REEP | Request for entry into the european phase |
Ref document number: 2008860304 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008860304 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12747762 Country of ref document: US |